tirzepatide cvot trial Post hoc analysis of SURPASS-CVOT trial: was associated with a lower risk of the 6-component cardiorenal endpoint, driven by reduction in all-cause mortality, compared to dulaglutide in patients with T2D and Can Dual Incretin Receptor Agonists
Pay in 4 interest-free payments of $6.47 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17




























![Entomb [Odyssey] 1HP095](https://cdn.shopify.com/s/files/1/0794/9162/9342/files/f60a2091-fb97-4f04-911b-fce9b6351044.png?v=1773761564)